Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.

UNLABELLED: Multidrug resistance (MDR) is a major challenge to the successful treatment of acute myeloid leukemia (AML). Our purpose was to determine whether (111)In-HuM195 anti-CD33 antibodies modified with peptides harboring nuclear localizing sequences (NLS) could kill drug-resistant AML cell li...

Descripción completa

Detalles Bibliográficos
Autores principales: Kersemans, V, Cornelissen, B, Minden, MD, Brandwein, J, Reilly, R
Formato: Journal article
Lenguaje:English
Publicado: 2008

Ejemplares similares

Ejemplares similares